CYP2E1 and breast cancer: Such controversy results may due to the relatively low mutation frequency of CYP2E1 and small epidemiologic studies with low statistic power; we therefore systematically reviewed and performed a meta-analysis to quantitatively evaluate the role of CYP2E1 polymorphisms in BC development.